M1415 HCPCS: Reimbursement & Policy Benchmarks | OpenPayer

Summary & Overview

HCPCS Level II M1415: No Positive PD-L1 Before First-Line Immunotherapy

HCPCS Level II code M1415 captures patients who did not have a positive PD-L1 biomarker expression test result documented before starting first-line immune checkpoint inhibitor therapy. The code supports standardized reporting of biomarker testing status in the context of first-line oncology immunotherapy, which matters nationally as PD-L1 status can influence treatment selection, coverage policies, and quality measurement. Consistent use of M1415 aids payers, providers, and health systems in tracking adherence to testing protocols and clarifying clinical rationale for therapy initiation when PD-L1 positivity is absent.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication outlines how M1415 is applied across outpatient oncology and infusion settings and summarizes where the code fits within billing and utilization workflows.

Readers will learn clinical context for the code, common sites of service, and the types of benchmarks and policy considerations relevant to reporting PD-L1 testing status prior to first-line immune checkpoint inhibitor therapy. The piece also highlights common modifiers associated with HCPCS billing and notes when additional documentation or coding may be required. Data not available in the input will be identified where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1415HCPCS Level IIPD-L1immune checkpoint inhibitorfirst-line immunotherapyoncology billingbiomarker reportingoutpatient infusion

Billing Code Overview

HCPCS Level II code M1415 denotes patients who did not have a positive PD-L1 biomarker expression test result prior to initiation of first-line immune checkpoint inhibitor therapy. This code is used to identify clinical situations where a PD-L1 positive result was not documented before starting first-line immunotherapy.

Service type: Documentation and reporting of biomarker testing status related to initiation of first-line immune checkpoint inhibitor therapy
Typical site of service: Oncology clinic, hospital outpatient oncology department, or other ambulatory infusion/infusion center settings where first-line immune checkpoint inhibitor therapy is initiated

Clinical & Coding Specifications

Clinical Context

A 64-year-old patient with newly diagnosed metastatic non–small cell lung cancer (adenocarcinoma) presents to the oncology clinic for initiation of first-line immune checkpoint inhibitor therapy. Tissue-based PD-L1 testing was performed on the diagnostic tumor specimen but returned a result that did not meet criteria for positive PD-L1 expression. The oncology team documents that therapy selection for an immune checkpoint inhibitor is being initiated despite lack of a positive PD-L1 biomarker result due to clinical factors (tumor histology, symptom burden, performance status, or contraindications to alternative regimens). Prior to treatment start, the clinic orders baseline labs, schedules infusion nursing and pharmacy preparation, obtains consent, and captures the billing code M1415 to denote that the patient did not have a positive PD-L1 test result before first-line immune checkpoint inhibitor therapy.

Typical site of service is an outpatient oncology infusion center or hospital outpatient infusion clinic. The workflow includes pathology report review, multidisciplinary discussion if needed, documentation of rationale for immunotherapy without PD-L1 positivity, preauthorization/insurance verification, infusion nursing visit, and periodic toxicity monitoring during follow-up visits.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services

HCPCS Level II M1245: Patient-Reported Provider Saw Me as a Person

HCPCS-M1293-BMI-ELEVATED-FOLLOW-UP-PLAN-DOCUMENTED

HCPCS Level II M1293: Elevated BMI with Follow-Up Plan Documented

HCPCS-M1239-PATIENT-DID-NOT-RESPOND-TO-HEARD-AND-UNDERSTOOD-QUESTION

HCPCS Level II M1239: Patient Did Not Respond to 'Heard and Understood' Question

HCPCS-M1210-HIGH-RISK-MEDICATION-ORDERS-NOT-ORDERED

HCPCS M1210: At Least Two High-Risk Medication Orders Not Ordered

HCPCS-M1348-PAM-SCORE-INCREASE-EXCELLENT

HCPCS M1348: Patient Activation Measure Increase, Excellent

HCPCS-M1437-TELEHEALTH-ENCOUNTER

HCPCS M1437: Encounters Conducted via Telehealth

HCPCS-M1485-HCV-NO-SUSTAINED-VIROLOGICAL-RESPONSE

HCPCS M1485: HCV No Sustained Virological Response

HCPCS-M1213-SPIROMETRY-NO-CONFIRMED-OBSTRUCTION-CURRENT-NON-OBSTRUCTIVE

HCPCS M1213: Spirometry Assessment, No Prior Confirmed Obstruction

HCPCS-M1314-BMI-NOT-DOCUMENTED

HCPCS Level II M1314: BMI Not Documented, No Reason Given

HCPCS-M1261-KIDNEY-WAITLIST-PRIOR-TO-DIALYSIS

HCPCS Level II M1261: Kidney/Kidney-Pancreas Waitlist Prior to Dialysis

Showing 1–10 of 356

Taxonomy Code	Specialty	Notes
207P00000X	Medical Oncology	Most common specialty ordering and overseeing first-line immune checkpoint inhibitor therapy.
2080P0201X	Hematology-Oncology	Specialists who manage systemic therapy for solid tumors including immunotherapy.
363L00000X	Oncology Nursing	Infusion nursing and care coordination in outpatient infusion centers.
207L00000X	Internal Medicine	Hospitalists or internists who may participate in inpatient initiation or comanagement.
208D00000X	Pathology	Pathologists perform and report PD-L1 testing and interpret biomarker results.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C34.90`	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Non–small cell lung cancer is a common indication for PD-L1 testing and first-line immune checkpoint inhibitor therapy even without positive PD-L1 expression.
`C50.912`	Malignant neoplasm of unspecified site of right female breast	Advanced or metastatic breast cancers may be considered for immunotherapy in select histologies; PD-L1 testing influences therapy choices.
`C61`	Malignant neoplasm of prostate	Included as a solid tumor diagnosis encountered in oncology practice; immunotherapy use is limited but may be considered in specific contexts.
`C18.9`	Malignant neoplasm of colon, unspecified	Colorectal cancers with certain biomarkers (e.g., mismatch repair deficient) may be treated with immune checkpoint inhibitors regardless of PD-L1 status.
`C80.1`	Malignant (primary) neoplasm, unspecified	Used when a specific primary site is not yet established at the time of treatment decision to proceed with immunotherapy without PD-L1 positivity.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Common for infusion of monoclonal antibody immune checkpoint inhibitors administered over approximately 30–60 minutes as the initial infusion session.
`96415`	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary infusion)	Used when infusion time exceeds the initial hour and additional time is required for immune checkpoint inhibitors.
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Alternative code sometimes used for therapeutic monoclonal antibody infusions when payer prefers non-chemotherapy administration coding.
`96366`	Intravenous infusion, each additional hour	Used when infusion duration extends beyond the initial hour for supportive IV therapies given with or around immunotherapy.
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs prior to initiation of immune checkpoint inhibitor therapy.
`88305`	Surgical pathology, gross and microscopic examination, intermediate complexity	Associated with pathology review of tumor specimen used for PD-L1 testing and diagnostic tissue evaluation.

OpenPayer